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Ibuprofen is one of the most important non-steroidal anti-inflammatory drugs used in the treatment of 
inflammatory diseases. In its pure state, ibuprofen presents poor physical and mechanical characteristics 
and its use in solid dosage forms needs the addition of excipients that improve these properties. The 
selection of the best excipients and the most suitable pharmaceutical dosage form to carry ibuprofen is 
very important for the industrial success of this drug. Given these factors, lipid microparticles and solid 
dispersions of ibuprofen with cetyl alcohol, stearic acid, and hydrogenated castor oil were prepared. These 
formulations were intended to improve the physical and mechanical characteristics and to sustain the 
release of this drug. Physical mixtures were also prepared with the same ingredients in similar proportions. 
The solid dispersions of ibuprofen/stearic acid and ibuprofen/hydrogenated castor oil showed the best flow 
characteristics compared with pure ibuprofen. Further, gelatin capsules filled with lipid microparticles 
and solid dispersions were submitted to dissolution tests in order to study the influence of the prepared 
systems in the release profiles of ibuprofen. Prolonged release of ibuprofen was achieved with the lipid 
microparticles and solid dispersions prepared with the different types of excipients.
Uniterms: Ibuprofen/solid dispersions/release profile. Ibuprofen/lipid microparticles/release profile. 
Excipients. Cetyl alcohol. Stearic acid. Hydrogenated castor oil.
O ibuprofeno é um dos antiinflamatórios não esteróides mais utilizados no tratamento de patologias 
associadas a processos inflamatórios. Este fármaco, quando no seu estado puro, apresenta características 
físicas e mecânicas pouco satisfatórias e a sua utilização em formas sólidas só é possível se forem 
adicionados excipientes que permitam melhorar estas propriedades. A seleção dos excipientes ideais e 
da forma farmacêutica mais adequada para veicular o ibuprofeno é fundamental para o sucesso industrial 
deste fármaco. Tendo em conta estes fatores, prepararam-se micropartículas lipídicas e dispersões sólidas 
de ibuprofeno com cada um dos seguintes excipientes: álcool cetílico, ácido esteárico e óleo de rícino 
hidrogenado. Estas formulações tinham por finalidade melhorar as características físicas e mecânicas 
e prolongar a liberação deste fármaco. Foram, também, preparadas misturas físicas do ibuprofeno com 
os mesmos excipientes e nas mesmas proporções. As dispersões sólidas de ibuprofeno/ácido esteárico 
e as dispersões sólidas de ibuprofeno/óleo de rícino hidrogenado foram aquelas que apresentaram 
melhores características de escoamento comparativamente com o ibuprofeno puro. Por outro lado, 
foram preparadas cápsulas de gelatina com as diferentes micropartículas lipídicas e dispersões sólidas e 
submetidas a ensaios de dissolução com o objetivo de estudar a influência dos sistemas preparados nos 
perfis de liberação do ibuprofeno. A liberação prolongada do ibuprofeno foi conseguida nas diferentes 
micropartículas lipídicas e dispersões sólidas preparadas com os diferentes excipientes. 
Unitermos: Ibuprofeno/dispersões sólidas/perfil de liberação. Ibuprofeno/micropartículas lipídicas/perfil 
de liberação. Excipients. Álcool cetílico. Ácido esteárico. Óleo de rícino hidrogenado.
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INTRODUCTION
Ibuprofen (IB) is a drug of the non-steroidal anti-in-
flammatory group (NSAIDs), belonging to the sub-group 
of drugs derived from propionic acid (Oswald, Guimarães, 
2001). It is generally well tolerated, but may trigger head-
aches, stomach pain, vomiting, diarrhea, stomach, and 
duodenal ulcers (Brunton et al., 2007). Therefore, there 
is a need to minimize these adverse effects and to prolong 
its anti-inflammatory action.
There are two key strategies to alter the release and 
subsequent absorption of drugs: one is based on modifica-
tion of the drug, and the other is based on modification of 
the dosage form (Lachman, 2001).
The preparation of solid dispersions is a strategy to 
change the release and subsequent drug absorption (Chiou, 
Riegelman, 1971a). The drug is well dispersed in a matrix 
of a material that modifies its release, encapsulated in the 
form of particles or compressed to form tablets. For the 
same purpose, lipid microparticles were prepared using 
the emulsion/chilling method.
The matrix systems are classified according to their 
chemical nature and release mechanism. Hydrophilic ma-
trices absorb water and form a gel prior to dissolution (e.g., 
methylcellulose, agar-agar, alginates, and carbomer) and 
hydrophobic matrices produce porous solid structures in 
which the drug is dispersed. Hydrophobic matrices include 
the inert matrices, which are insoluble in gastric juices 
(e.g., cellulose acetate, ethyl cellulose, etc.), and lipid 
matrices that undergo erosion, gastric enzyme lipolysis, 
or solubilization by ionization (e.g., hydrogenated castor 
oil, stearic acid, and cetyl alcohol). The choice of matrix 
is very important, because this choice will influence the 
ability of the formulation to control the drug release and 
thereby sustain the therapeutic action over time (Liberal, 
2008; Salomen, 1980). Waxes and other related lipidic ma-
terials such as cetyl alcohol, stearic acid, and hydrogenated 
castor oil form matrices that control the release of drugs by 
diffusion through pores or by erosion (Rowe et al., 2003).
Solid dispersions
The term “solid dispersion” describes the disper-
sion of one or more active substances in a carrier or inert 
solid matrix prepared by melting, using solvents, or by a 
solvent-melting method (Chiou, Riegelman, 1971b).
Solid dispersions may have several advantages and 
pharmaceutical applications, including: the uniform and 
homogeneous distribution of small quantities of drug in the 
solid state; the stabilization of unstable drugs; the disper-
sion of liquid or gaseous compounds; and the production 
of prolonged release systems or the increase of drug dis-
solution rates.
The combination of a slightly soluble drug in wa-
ter with a water-soluble matrix results in a rapid-release 
drug formulation (e.g., solid dispersion of ibuprofen/PEG 
4000 or ibuprofen/PEG 8000), can be used to increase 
the dissolution rate of the drug (Newa, 2008). Another 
example is the solid dispersion of ibuprofen in Poloxamer 
407 in order to increase the solubility and consequently 
the dissolution rate of the drug (Newa, 2008). Moreover, 
the combination of a water-soluble drug with a slightly 
water-soluble matrix sustains the drug release from the 
matrix. The characteristics of drug release can be altered 
by changing the ratio between the drug and excipient 
(Ford, Rubinstein, 1978).
To disperse a drug in an excipient, several methods 
can be used, including the solvent method (Ford, 1986), 
the fusion method (Sharma, Joshi, 2007; Yi et al., 2008), 
the solvent-melting method, as well as freeze- and spray-
drying technology (Park et al., 2009).
Lipid microparticles
Microparticles, as seen in solid dispersions, arise 
from the need to overcome possible adverse effects and 
to increase the short half-life of some drugs. The main 
advantages are the fact that they present a great biocompat-
ibility, low toxicity, high stability, and improve efficacy, 
absorption, and bioavailability. They can also facilitate the 
administration, masking the organoleptic properties and 
protecting the drug (Kumar, 2000).
The microparticles have dimensions that can vary 
between 1 µm and 1000 µm; however, some authors have 
considered particles larger than 1 mm as microparticles.
The microparticles can be classified as reservoirs 
or matrices. In the first case, the drug is at the core and is 
surrounded by a layer or film coating, which can be semi-
permeable or completely permeable. In the second case, 
the drug is homogeneously dispersed in a matrix of irregu-
lar geometry and that is sometimes porous. The drug can 
be found on the surface of the matrix in direct contact with 
the external environment. There are several methodologies 
for the production of microparticles reflecting the physico-
chemical properties of the drug in order to maintain their 
unique therapeutic properties. However, there are other 
factors to take into account such as: the environmental 
impact of the process; ease of implementation; availability 
of equipment and resources; cost; and process efficiency. 
The methods for the production of lipid microparticles in-
clude: spray-drying technology (Mahajan, Gattani, 2009); 
double-emulsion solvent evaporation (Freitas et al., 2005); 
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emulsion/chilling, the solvent method (Soppimath, 2001); 
the engineering division, fluid supercritical (Kang et al., 
2008); atomization and modified atomization; fluidized 
bed (Gouin, 2004); and extrusion.
MATERIAL AND METHODS
Material
Ibuprofen (Lot No. 0507939, Roig Farma, Spain), 
cetyl alcohol (Lanette 16) (Lot No. S383040010, José M. 
Vaz Pereira SA, Portugal), stearic acid (Lot No. 062,821, 
Acofarma, Spain), hydrogenated castor oil (Cutina HR®) 
(Lot No. CG42720170, José M. Vaz Pereira SA, Portugal), 
monosodium phosphate (Lot No. 0194, José M. Vaz Perei-
ra, SA, Portugal), disodium phosphate anhydrous (Lot No. 
130470JR, José M. Vaz Pereira, SA, Portugal), propylene 
glycol (Lot No. VF251920D4, José M. Vaz Pereira, SA, 
Portugal) and chloroform (Lot No. 7B128128C, Pronolab, 
José M. Vaz Pereira, SA, Portugal). Gelatin capsules No. 
0 (Lot No. 9328900023, Guinama, Spain).
Methods
Preparation of solid dispersions containing ibuprofen 
Solid dispersions at a 1:2 ratio of ibuprofen/ex-
cipient were prepared using the fusion method. This ratio 
was used to make certain that the excipient contained the 
ibuprofen, in order to obtain the sustained release of the 
ibuprofen.
Excipient melting (variable temperature according 
to the melting point of the excipients) on a hot plate under 
stirring was used, followed by addition of ibuprofen to the 
excipient cast, slow cooling for solidification of the mass, 
and grinding.
Gelatin capsules No. 0 were filled with these solid 
dispersions (method - capsule filling plate).
Preparation of lipid microparticles containing ibuprofen
Lipid microparticles of 1:2 ibuprofen/excipient 
ratio were prepared using the emulsion/chilling method. 
Excipients were melted (variable temperature according 
to the melting point of the excipients) on a hot plate un-
der stirring at 600 rpm (in order to achieve particles with 
micrometric size) and ibuprofen was added to the molten 
excipient. The oil phase was slowly added to a 1.5 % (w/w) 
Tween® 80 solution at the same temperature, followed by 
the quick addition of a mixture of water:propylene glycol 
(75:25) at 0 °C, maintaining the agitation at 600 rpm. The 
microparticles obtained were filtered and washed with 
water. Gelatin capsules No. 0 were filled with these lipid 
microparticles (method - capsule filling plate).
Preparation of physical mixtures containing ibuprofen
Physical mixtures of 1:2 ibuprofen/excipient were 
also prepared, using a Turbula WAB T2F (Switzerland) 
for 15 minutes.
Determination of particle size-distribution
The test was performed in the Retsh AS 200 Digit 
(Germany), for the dry sieving. Sieves with the following 
mesh diameter were chosen: 1000 µm, 500 µm, 355 µm, 
180 µm, 125 µm, and 90 µm. Samples were weighed (50 g) 
and submitted to a 2.0 mm amplitude vibration, for two 
cycles of 5 minutes. Tests were performed in triplicate, and 
the results shown are the average of the obtained values.
Determination of flow rate and repose angle
For these tests, a Granulate Flow Tester, Erweka 
Type: GT / GTB (Germany) was used. A funnel with a 
metal tip with a hole of 15 mm and 50 g of solid disper-
sions or lipid microparticles were used. The tests were 
performed in triplicate, with the results shown being the 
average of the obtained values.
Determination of ibuprofen content using UV-VIS 
spectrophotometry
For the determination of ibuprofen content in solid 
dispersions and lipid microparticles, 75 mg of each sample 
was dissolved in chloroform (50 mL) and analyzed by 
UV-VIS spectrophotometry (UV-VIS spectrophotometer 
JASCO V-650, Japan) at 272 nm. The accuracy, repeat-
ability, specificity, and linearity of the spectrophotometric 
method were previously evaluated.
Mass uniformity of capsules
Mass uniformity test of gelatin capsules filled with 
the solid dispersions and lipid microparticles was per-
formed. Twenty individually weighed units of capsules 
containing solid dispersions or lipid microparticles were 
taken at random and the average mass was determined.
In vitro dissolution test
For this study, gelatin capsules containing solid dis-
persions or lipid microparticles and capsules containing 
only pure ibuprofen were used. 
Dissolution tests were performed under the follow-
ing conditions: 
Dissolution apparatus - SOTAX AT7 (Switzerland); 
Basket method;
Agitation speed - 100 rpm; 
Temperature – 37.0 ± 0.5 ºC; 
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Dissolution liquid - pH 7.4 phosphate buffer solution 
(Portuguese Pharmacopoeia VIII);
Dissolution liquid volume - 500 mL;
Sample bulk - 10.0 mL;
Collection times - 30, 60, 120, 240, 360, 600 minutes. 
Samples were assayed in triplicate in a UV-VIS 
spectrophotometer at 272 nm, using pH 7.4 buffer phos-
phate solution as a blank. 
RESULTS AND DISCUSSION
Determination of particle size-distribution
Figure I show the particle size-distribution of the dif-
ferent solid dispersions. Solid dispersions of ibuprofen in 
hydrogenated castor oil and stearic acid presented a higher 
percentage of particles with average size >1000 µm. The 
solid dispersion of ibuprofen in cetyl alcohol showed a 
higher percentage of particles between 500 and 1000 µm. 
Figure 2 shows the particle size-distribution of the 
different lipid microparticles. The lipid microparticles of 
ibuprofen in hydrogenated castor oil and stearic acid pre-
sented a higher percentage of particles with average size 
>1000 µm. The microparticles of cetyl alcohol showed a 
more heterogeneous size distribution.
Determination of flow rate and repose angle
The pure ibuprofen power did not flow. Similarly, 
physical mixtures of ibuprofen with each excipient did 
not flow. In all cases, the particles of the physical mixtures 
stayed stuck to the funnel wall. 
The solid dispersion of ibuprofen in cetyl alcohol 
(SD CA) did not show flowability. 
On the other hand, the solid dispersion of ibuprofen 
in stearic acid (SD SA) showed a flowability of 6.0 ± 0.28 s 
and a repose angle of 44.5 ° ± 0.31. The solid dispersion of 
ibuprofen in hydrogenated castor oil (SD HCO) presented 
a flowability of 5.3 ± 0.06 s and a repose angle of 41.9 ° ± 
1.22. The higher percentage of smaller particles presented 
by cetyl alcohol solid dispersions and also the adhesive 
forces and/or binding between particles had influence on 
its lack of flowability. 
None of the lipid microparticles formulated with 
different excipients presented flow characteristics.
Determination of ibuprofen using UV-VIS 
spectrophotometry
For ibuprofen UV-VIS spectrophotometry determi-
nation, several validation parameters were evaluated. The 
method showed specificity, good linearity (coefficient of 
determination of 0.999), accuracy (101.30% ± 2.55), and 
repeatability (CV = 0.34%) within the range of concentra-
tions assayed. 
Table I presents the content of ibuprofen in the solid 
dispersions prepared with the different types of excipients, 
i.e., cetyl alcohol, stearic acid, and hydrogenated castor oil.
The results of the determination of ibuprofen content 
in the different solid dispersions showed percentages of 
drug around 100% in all cases.
Table II presents the content of ibuprofen in the 
lipid microparticles prepared with the different types of 
excipients, i.e., cetyl alcohol, stearic acid, and hydroge-
nated castor oil.
FIGURE 1 – Size distribution of the solid dispersions of 
ibuprofen (SD CA- solid dispersions of cetyl alcohol; SD SA - 
solid dispersions of stearic acid; SD HCO - solid dispersions 
of hydrogenated castor oil).
FIGURE 2 – Size distribution of the lipid microparticles of 
ibuprofen (LM CA- lipid microparticles of cetyl alcohol; LM 
SA - lipid microparticles of stearic acid; LM HCO - lipid 
microparticles of hydrogenated castor oil).
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TABLE I – Ibuprofen content in solid dispersions
Solid dispersions % of ibuprofen
SD CA 101.95
SD SA 103.72
SD HCO 98.31 
(SD CA- solid dispersions of cetyl alcohol; SD SA - solid 
dispersions of stearic acid; SD HCO - solid dispersions of 
hydrogenated castor oil).
TABLE II – Ibuprofen content in lipid microparticles




(LM CA- lipid microparticles of cetyl alcohol; LM SA - lipid 
microparticles of stearic acid; LM HCO - lipid microparticles 
of hydrogenated castor oil).
TABLE III – Results of mass uniformity of capsules prepared with ibuprofen and the different solid dispersions
Capsules Average (mg) Maximum Minimum SD CV (%)
IB 415.52 398.43 437.72 11.82 2.85
SD CA 399.08 376.58 419.60 12.21 3.06
SD SA 415.25 401.57 428.23 5.59 1.35
SD HCO 435.64 411.65 453.88 9.04 2.07
(IB – Ibuprofen; SD CA- solid dispersions of cetyl alcohol; SD SA - solid dispersions of stearic acid; SD HCO - solid dispersions 
of hydrogenated castor oil).
TABLE IV – Results of mass uniformity of capsules filled with ibuprofen and the different lipid microparticles
Capsules Average (mg) Maximum Minimum SD CV (%)
IB 415.52 398.43 437.72 11.82 2.85
LM CA 340.85 320.98 358.45 11.25 3.30
LM SA 393.52 361.71 414.65 15.98 4.06
LM HCO 340.16 306.48 366.20 18.67 5.49
(IB – Ibuprofen; LM CA- lipid microparticles of cetyl alcohol; LM SA - lipid microparticles of stearic acid; LM HCO - lipid 
microparticles of hydrogenated castor oil).
As can be seen in Table III, the mass of capsules 
was within the limits of Portuguese Pharmacopoeia VIII.
Table IV show the values of mass uniformity of gela-
tin capsules filled with the different lipid microparticles.
From the analysis of the results for uniformity 
of mass it can be seen that only the masses of capsules 
containing IB or LM CA (lipid microparticles of cethyl 
alcohol) remained within the limits specified by the Por-
tuguese Pharmacopoeia.
In vitro dissolution test
After the characterization of capsules, in vitro dis-
solution studies were performed. Validation parameters 
of the method for ibuprofen determination (UV-VIS 
spectrophotometry) were evaluated. The method showed 
specificity, good linearity (coefficient of determination 
of 0.9994), accuracy (100.43% ± 1.97), and repeatability 
(CV = 0.18%) within the range of concentrations studied. 
Figure 3 shows the dissolution profiles of pure ibu-
profen and solid dispersions of this drug in cetyl alcohol, 
stearic acid, or hydrogenated castor oil contained in gelatin 
capsules.
As can be seen in Figure 3, due to its crystalline 
structure, about 95 % of pure ibuprofen was dissolved 
in the first 30 minutes of the dissolution test. Due to the 
water-in-oil emulsion properties of cetyl alcohol, solid 
dispersions of this excipient showed a higher percentage 
of ibuprofen released (62.8 %) after 30 minutes, followed 
by solid dispersions of stearic acid (48.1%), and solid 
dispersion of hydrogenated castor oil (41.0 %). After 
The results of the determination of ibuprofen content 
in the different lipid microparticles showed different per-
centages of drug. Lipid microparticles of stearic acid and 
hydrogenated castor oil showed a percentage of ibuprofen 
below 90%.
Mass uniformity of capsules
Table III shows the values of mass uniformity of gela-
tin capsules prepared with the different solid dispersions.
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10 hours of testing, the amount of ibuprofen released from 
the solid dispersions of cetyl alcohol and stearic acid was 
almost identical (80 %), while the solid dispersion of hy-
drogenated castor oil released 70.5 % of drug. However, 
the solid dispersion of hydrogenated castor oil showed 
a dissolution profile similar to the solid dispersion of 
stearic acid (Similarity factor = 58.7) (Prista et al., 1996). 
Comparing the solid dispersion of cetyl alcohol (SD CA) 
and the solid dispersion of hydrogenated castor oil (SD 
HCO), it can be concluded that these two types of solid 
dispersion presented different profiles (Similarity factor 
= 40.0) (Prista et al., 1996).
Figure 4 shows the dissolution profiles of pure 
ibuprofen and lipid microparticles of the drug in cetyl al-
cohol, stearic acid, and hydrogenated castor oil contained 
in gelatin capsules.
As observed in solid dispersions, and due to the 
emulsifying properties of cetyl alcohol, lipid micropar-
ticles of this excipient have a greater release of drug dur-
ing the first 30 minutes of testing. These microparticles 
released 81.4% of drug within 30 minutes. However the 
lipid microparticles of stearic acid and hydrogenated cas-
tor oil released only about 40 % of ibuprofen.
The lipid microparticles of cetyl alcohol after 10 
hours of testing had a percentage of 97.7% of drug released 
and the lipid microparticles of stearic acid released 94.5% 
of the drug.
Regarding the lipid microparticles of hydrogenated 
castor oil, they showed only 59.6% of drug dissolved after 
10 hours of testing. The microparticles of cetyl alcohol 
had a dissolution profile different of the microparticles 
of stearic acid (f2 = 33.4) and hydrogenated castor oil 
(f2 = 22.6).
Physical mixtures were not evaluated in terms of 
dissolution rate because it was expected that this system 
would not allow the sustained release of drug.
The presence of lipids appears to affect the crystal-
line organization of ibuprofen. Solid dispersions and solid 
lipid microparticles were highly in amorphous form, in 
contrast to pure ibuprofen, which contributed to a decrease 
of dissolution/release of this drug. Besides, the sustained 
release profiles of solid dispersions and lipid micropar-
ticles can be attributed to the entrapment of drug in the 
lipid matrices.
CONCLUSIONS
The results of this work show that the type of ex-
cipients used to prepare solid dispersions and solid lipid 
microparticles influence the physical and mechanical 
properties, as well as the dissolution profiles of ibuprofen.
Solid dispersions of ibuprofen in stearic acid and 
hydrogenated castor oil showed better flow characteristics 
than pure ibuprofen and the respective physical mixtures. 
However, none of the solid lipid microparticles formulated 
with different excipients presented flow characteristics.
Sustained-release of ibuprofen was achieved with 
the preparation of solid dispersions and solid lipid mic-
roparticles using cetyl alcohol, stearic acid, and hydroge-
nated castor oil.
Due to their emulsifying properties, systems with 
cetyl alcohol presented higher percentages of ibuprofen 
released than stearic acid or hydrogenated castor oil. 
However, solid dispersions of ibuprofen in hydrogenated 
FIGURE 3 - Dissolution profiles of solid dispersions of 
ibuprofen with different excipients (IB – Ibuprofen; SD CA- 
solid dispersions of cetyl alcohol; SD SA - solid dispersions of 
stearic acid; SD HCO - solid dispersions of hydrogenated 
castor oil).
FIGURE 4 - Dissolution profiles of lipid microparticles of 
ibuprofen with different excipients (IB – Ibuprofen; LM 
CA- lipid microparticles of cetyl alcohol; LM SA - lipid 
microparticles of stearic acid; LM HCO - lipid microparticles 
of hydrogenated castor oil).
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castor oil showed better flow characteristics and a more 
prolonged release of ibuprofen. These systems are easy 
to prepare and may lead to the avoidance of frequent drug 
administration.
LIST OF ABBREVIATIONS 
IB – Ibuprofen
LM CA – Lipid Microparticles of Cetyl Alcohol
LM HCO – Lipid Microparticles of Hydrogenated Castor 
Oil
LM SA – Lipid Microparticles of Stearic Acid
PEG – Poly(ethylene glycol)
SD CA – Solid Dispersions of Cetyl Alcohol
SD HCO – Solid Dispersions of Hydrogenated Castor Oil
SD SA – Solid Dispersions of Stearic Acid
UV-VIS – Ultraviolet-Visible
REFERENCES
BRUNTON, L.L.; LAZO J.S.; PARKER K.L. (Eds.). Goodman 
& Gilman’s: as bases farmacológicas da terapêutica. 11.ed. 
Columbus: McGraw-Hill, 2007. p.1821.
CHIOU, W.L.; RIEGELMAN, S. Pharmaceutical applications 
of solid dispersion systems. Pharm. Acta Helv., v.60, n.9, 
p.1281-1301, 1971.
FORD, J.L.; RUBINSTEIN, M.H. Phase equilibria and 
dissolution rates of indomethacin-polyethylene glycol 6000 
solid dispersions. Pharm. Acta Helv., v.53, n.11, p.327-332, 
1978.
FORD, J.L. The current status of solid dispersions. Pharm. Acta 
Helv., v.61, n.3, p.69-88, 1986.
FREITAS, S.; MERKLE, H.P.; GANDER, B. Microencapsulation 
by solvent extraction/evaporation: reviewing the state of 
the art of microsphere preparation process technology. J. 
Control. Release., v.102, n.2, p.313-332, 2005.
GOUIN, S. Microencapsulation: industrial appraisal of existing 
technologies and trends. Trends Food Sci. Technol., v.15, 
n.7-8, p.330-347, 2004.
KANG, Y.; YIN, G.; OUYANG, P.; HUANG, Z.; YAO, Y.; 
LIAO, X.; CHEN, A.; PU, X. Preparation of PLLA/PLGA 
microparticles using solution enhanced dispersion by 
supercritical fluids (SEDS). J. Colloid Interface Sci., v.322, 
n.1, p.87-94, 2008.
KUMAR, M.N.V. Nano and microparticles as controlled drug 
delivery devices. J. Pharm. Sci., v.3, n.2, p.234-258, 2000.
LACHMAN, L. Teoria e prática na indústria farmacêutica. 1.ed. 
Lisboa: Fundação Calouste Gulbenkian, 2001. p.737-738.
LIBERAL, J.P.M. Desenvolvimento e caracterização de 
comprimidos matriciais de dupla camada contendo 
Paracetamol. Porto, 2008. p.112. [Dissertation of Master 
Degree. Faculty of Pharmacy. University of Porto].
MAHAJAN, H.S.; GATTANI, S.G. Gellan gum based 
microparticles of metoclopromide hydrochloride for 
intranasal delevery: development and evaluation. Chem. 
Pharm. Bull., v.57, n.4, p.388-392, 2009.
NEWA M. Preparation and evaluation of immediate release 
ibuprofen solid dispersions using polyethylene glycol 4000. 
Biol. Pharm. Bull., v.31, n.5, p.939-945, 2008.
NEWA, M. Enhancement of solubility, dissolution and 
bioavailability of ibuprofen in solid dispersion systems. 
Chem. Pharm. Bull., v.56, n.4, p.569-574, 2008.
NEWA, M. Enhanced dissolution of ibuprofen using solid 
dispersion with poloxamer 407. Arch. Pharm. Res., v.31, 
n.1, p.1497-1507, 2008.
OSWALD, W.; GUIMARÃES, S. Terapêutica medicamentosa 
e suas bases farmacológicas. 4.ed. Porto: Porto Editora, 
2001. p.1296. 
PARK, Y.J.; KWON, R.; QUAN, Q.Z.; OH, D.H; KIM, J.O.; 
HWANG, M.R.; KOO, Y.B.; WOO, J.S.; YONG, C.S.; 
CHOI, H.G. Development of novel ibuprofen-loaded solid 
dispersion with improved bioavailability using aqueous 
solution. Arch. Pharm. Res., v.32, n.5, p.767-772, 2009.
ROWE, R.C.; SHESKEY, P.J.; WELLER, P.J. Handbook 
of pharmaceutical excipients. 4.ed. Washington: The 
Pharmaceutical Press,  American Pharmaceutical 
Association, 2003. p.776. 
SALOMEN, J.L.; DOELKER, E. Formulation of sustained 
release tablets. I. Inert matrices. Pharm. Acta Helv., v.55, 
n.7, p.174-182, 1980.
SHARMA, D.K.; JOSHI, S.B. Solubility Enhancement 
Strategies for Poorly Water-Soluble Drugs in Solid 
Dispersions: A Review. Asian J. Pharm., v.1, n.1, p.9-19, 
2007.
H. Almeida, M. H. Amaral, P. Lobão536
SOPPIMATH, K.S.; KULKARNI, A.R.; AMINABHAVI, T.M. 
Encapsulation of antihypertensive drugs in cellulose matrix 
microspheres: characterization and release of microspheres 
and tableted microspheres. J. Microencapsul., v.18, n.3, 
p.397-409, 2001.
YI, H.G.; CHI, M.H.; KIM, Yo; WOO, J.S.; PARK E. 
Formulation of a extended release tablet containing 
dexibruprofen. Arch. Pharm. Res., v.31, n.12, p.1637-1643, 
2008.
Received for publication on 1st November 2011
Accepted for publication on 27th April 2012
